Crystal Pharmatech Co., Ltd.

Crystal Pharmaceutical (suzhou) Co., Ltd.

Receptos, Inc.

Suzhou Pengxu Pharmatech Co., Ltd.

Merck Sharp + Dohme Corp.

Glaxosmithkline Intellectual Property (no.2) Limited

Anacor Pharmaceuticals, Inc.

Genzyme Corporation

Crystal Pharmatech Inc.

Crystal Pharmaceuticals (suzhou) Co., Ltd.

Crystal Pharmaceutical Co., Ltd.

Minhua Chen

Yanfeng Zhang

Xiaoyu Zhang

Chaohui Yang

Xiaoting Zhai

Kaiqiang Yan

Kai Liu

Xiaojuan Diao

Po Zou

Nan Xia

Fei Lu

Jiaoyang Li

Jinqiu Wang

Peng Wang

Pixu Li

Chunxiang Huang

Liang Zhang

Qiyue Liu

Jing Zhang

Yuhao Chen

Shu Yu

Jianming Wang

Yuan Liu

Hui Gao

Jiale Qian

Cunbo Yang

Lie Chen

Shulin Ji

Heng Ge

Paolo Avalle

Siming Zou

Hongyan Zhu

Jiaming Shi

Xingjuan Chang

Novel crystalline forms of Resmetirom (Referred to as “Compound I”), and preparation methods thereof, pharmaceutical compositions containing the crystalline forms, and uses of the crystalline forms for preparing THR-β selective agonist drugs and drugs for treating NASH and HeFH. Compared with prior arts, the provided crystalline forms of Compound I have one or more improved properties, which is of great value to the optimization and development of the drugs containing Compound I.

Resmetirom crystal, preparation method for same, and uses thereof

The present disclosure relates to a novel crystalline form of Tolebrutinib (hereinafter referred to as “Compound I”) and preparation methods thereof, pharmaceutical compositions containing the crystalline form, and uses of the crystalline form for preparing BTK inhibitor drugs and drugs for treating multiple sclerosis.

Crystalline form of Tolebrutinib

The present disclosure relates to novel crystalline forms of ozanimod and preparation method thereof. The provided crystalline forms of ozanimod comprise crystalline form CS9, crystalline form CS10 and crystalline form CS11, and can be used for treating autoimmune diseases, particularly used for preparing drugs for treating multiple sclerosis and ulcerative colitis. The crystalline forms of the present disclosure have one or more advantages in solubility, stability, hygroscopicity and processability and provide new and better choices for the preparation of ozanimod drug product, and are very valuable for drug development.

Crystalline forms of ozanimod and processes for preparation thereof

Provided are novel crystalline forms of Lanifibranor (Referred to as 'Compound I') and preparation methods thereof, pharmaceutical compositions containing the crystalline forms, and uses of the crystalline forms for preparing pan-PPAR agonists drugs and drugs for treating NASH. Compared with prior arts, the provided crystalline forms of Compound I have one or more improved properties, which solve the problems of the prior art and is of great value to the optimization and development of the drugs.

Crystal form of lanifibranor, preparation method therefor, and use thereof

The present disclosure relates to novel crystalline forms of tafamidis (hereinafter referred to as compound I) and processes for preparation thereof. The present disclosure also relates to pharmaceutical composition containing the novel crystalline forms, use of the novel crystalline forms for preparing drugs treating disease caused by transthyretin-mediated amyloidosis. The crystalline forms of tafamidis of the present disclosure have one or more improved properties compared with crystalline forms of prior art and have significant value for future drug optimization and development.

Crystal form of tafamidis and preparation method therefor and use thereof

The present invention relates to four crystal forms of crisaborole in free form and the preparation method thereof. The present invention also relates to the pharmaceutical composition containing the crystal forms and the use thereof.

Crystal forms of crisaborole in free form and preparation method and use thereof

The present disclosure is directed to novel crystalline forms of ozanimod and ozanimod hydrochloride, as well as preparation method thereof. Said crystalline forms of ozanimod and ozanimod hydrochloride can be used for treating autoimmune diseases, particularly used for preparing drugs for treating multiple sclerosis and ulcerative colitis. The crystalline forms of the present disclosure have one or more advantages in solubility, melting point, stability, dissolution, bioavailability and processability and provide new and better choices for the preparation of ozanimod drug product, and are very valuable for drug development. 

Crystalline forms of ozanimod and ozanimod hydrochloride, and processes for preparation thereof

The present disclosure relates to crystalline form CS1 and CS9 of a hypoxia-inducible factor prolyl hydroxylase inhibitor compound (I) GSK1278863, processes for preparation, and uses for preparing drugs treating and/or preventing anemia thereof. 

Crystalline forms of GSK1278863, preparation method and pharmaceutical use thereof

Crystalline forms of upadacitinib and processes for preparation thereof are disclosed. The present disclosure also relates to pharmaceutical compositions containing the upadacitinib crystalline forms, use of the upadacitinib crystalline forms for preparing JAK1 inhibitor drugs, and use of the upadacitinib crystalline forms for preparing drugs treating rheumatoid arthritis, Crohn's disease, ulcerative colitis, atopic dermatitis and psoriatic arthritis. The crystalline forms of upadacitinib provided by the present disclosure have one or more improved properties compared with prior arts and have significant values for future drug optimization and development. 

Crystal form of upadacitinib, preparation method therefor, and use thereof

A crystalline form of valbenazine ditosylate, processes for preparation thereof, a pharmaceutical composition containing the crystalline form, use of the crystalline form for preparing vesicular monoamine transporter 2 inhibitor drugs, and use of the crystalline form for preparing drugs treating tardive dyskinesia.

Crystalline form of valbenazine ditosylate, processes for preparation thereof and use thereof

The present disclosure relates to a crystalline form of compound I and processes for preparation thereof. The present disclosure also relates to a pharmaceutical composition containing the crystalline form, use of the crystalline form for preparing serotonin, norepinephrine and dopamine triple reuptake inhibitors drugs, and/or use of the crystalline form for preparing drugs treating nervous system disorders. The crystalline form of the present disclosure has one or more improved properties compared with prior art and has significant values for future drug optimization and development. 

Crystalline form of EB-1020, processes for preparation and use thereof

The present disclosure relates to novel crystalline forms of compound (I) and processes for preparation and use thereof. Crystalline forms CS3, CS2, CS5 and CS8 of compound (I) of the present disclosure have advantages in at least one aspect of solubility, stability, melting point, hygroscopicity, particle size, bioavailability, processability, purification effect, flowability, adhesiveness, stability in drug product, in vitro and in vivo dissolution, etc., which provides new and better choices for preparation of drug product containing compound (I) and has significant values for future drug development. 

Crystalline forms of a fatty acid bile acid conjugate, preparation method thereof and use thereof

The present disclosure relates to crystalline forms of Baricitinib and processes for preparation thereof. The present disclosure also relates to pharmaceutical composition containing these crystalline forms and use of these crystalline forms for preparing JAK inhibitor drugs and preparing drugs treating rheumatoid arthritis. The crystalline forms of the present disclosure have one or more improved properties compared with crystalline forms of the prior art and have significant values for future drug optimization and development. 

Crystal form of Baricitinib and preparation method thereof

The present disclosure is related to crystalline forms of ozanimod hydrochloride, as well as preparation method thereof. The crystalline form of ozanimod hydrochloride provided by the present disclosure can be used for treating autoimmune diseases, particularly multiple sclerosis and ulcerative colitis. The crystalline form of the present disclosure has advantages in at least one aspect of solubility, melting point, stability, dissolution, bioavailability and processability and provides a new and better choice for the preparation of drug product containing ozanimod, and has significant value for drug development. 

Crystalline form of ozanimod hydrochloride, and processes for preparation thereof

Growing community of inventors

Suzhou, China

Minhua Chen